Crown Biosciences Inc.
11011 Torreyana Road, Suite 200
About Crown Biosciences Inc.
Crown Bioscience Inc. is a cutting edge translational technology company providing drug discovery and clinical development services in the areas of oncology, inflammation, cardiovascular, and metabolic disease.
CrownBio brings clarity to drug discovery and enables clients around the world to deliver superior clinical candidates. Our premier Translational Platforms for cancer, inflammation, and metabolic disease help our clients accelerate their new drug development programs. We develop world-leading preclinical efficacy models and provide both in vitro and in vivo testing services as well as preclinical research products.
CrownBio also provides preclinical immunotherapy research platforms to support the successful transition of immunotherapeutics from the lab into the clinic including models for the evaluation of CAR-T therapies, syngeneics, and humanized models.
We are a global company with facilities across the world in the United States, United Kingdom, China, and Taiwan. Our team of 525 experts, comprising highly trained PhD and MS scientists, provides services to Pharmaceutical, Biotechnology companies, and Biomedical Research Institutes around the world.
For more information, please visit our web site at www.crownbio.com.
Stock Exchange: TWSE (Taiwan Stock Exchange)
Stock Symbol: Ticker 6554
96 articles with Crown Biosciences Inc.
JSR affiliate companies Crown Bioscience, KBI Biopharma, Inc., Medical & Biological Laboratories Co., LTD., Selexis SA and other affiliates throughout Europe and the Asia-Pacific region.
The area is home to numerous well-known players in the pharma industry, including Abbott, Iovance, Gossamer Bio, Crown Biosciences, Illumina, Human Longevity and many, many more.
CrownBio Expands Genetically Engineered Model Selection Via Strategic Alliance with Shanghai Model Organisms Center (SMOC)Alliance enables researchers to access thousands of GEMMs
Crown Bioscienc has entered a strategic alliance with Shanghai Model Organisms Center (SMOC) to exclusively license and commercialize SMOC’s comprehensive collection of genetically engineered models.
CrownBio Enters Partnership with Pierre Fabre to Accelerate Discovery and Development of Immuno-Oncology Agents
Crown Bioscience announces that it has been selected by Pierre Fabre Research Institute as one of their partners to advance their immuno-oncology drug discovery pipeline.
CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody
Crown Bioscience and a global drug discovery and development services company announced a strategic licensing agreement with CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company.
Crown Biosciences: Enhanced MuScreen Platform Revolutionizes Preclinical Development of Immunotherapeutics
Immunotherapies, alone or in combination with other drugs, treat cancer by modulating the immune system to elicit native antitumor immune responses.
Data on Novel Humanized Models for Targeted Immunotherapy Development, a CrownBio Conference Talk on January 24th, 2018
Compelling data will showcase the utility of CrownBio’s humanized platform to comprehensively and reliably evaluate targeted immunotherapies, reduce cost of development and shorten experimental timelines.
Innovative Humanized Research Strategies for Immuno-Oncology Drug Development, Crown Bioscience Hosts a Live Webinar
Dr. Thatte will review currently available humanized models and describe innovative applications for preclinical immuno-oncology research.
12/20/2017The parent company of JSR Life Sciences snapped up CRO Crown Bioscience International for $400M, the company announced this morning.
Novel Preclinical Research Tools Provide Humanized Immune Response to Advance Immunotherapeutic Development, Live Webinar Hosted by Crown Bioscience
This webinar will introduce novel tools for investigating human immune response in immunocompetent systems.
Crown Bioscience Enhances Its European Capabilities With New Generation Of Innovative Translational Models For Obesity And Diabetes
Crown Bioscience Names Laurie Heilmann Chief Business Officer; Executive Leader Brings Expertise In Global Strategy And Commercial Leadership To The Role
Crown Bioscience’s Integrated Oncology Platform Helps Advance Apogenix’s Promising HERA-GITRL Immunotherapy For NSCLC And Head And Neck Cancer
Crown Bioscience Announces Second Quarter Results, Appoints Dr. Yangzhou Wang As Sr. VP Of Global Operations
Crown Bioscience Demonstrates Scientific Advancements In Metabolic Disease With A Validated And Improved Translatable Model For Obesity And Type 2 Diabetes Drug Discovery